NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

NovaBridge Biosciences (NBP) Stock Analysis

NovaBridge Biosciences (NBP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NBP

$1.37

−$0.05 (−3.86%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NBP with… →

NBP Key Statistics

As of Oct 21, 2026
Trading
Open
$1.43
Previous Close
$1.43
Day's Range
1.34–1.43
52-Week Range
1.26–5.19
Volume
586.51K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.60
Valuation
Market Cap
$158.92M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.69
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$46.27M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
116.00M
1-Year Return
−73.29%
Dividend and dates
Avg Volume
402.13K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NBP closed at $1.37, −73.29% over 1 year.

NovaBridge Biosciences (NBP) has a market capitalization of $158.92M.

In fiscal 2025, NBP reported revenue of $0.00.

NBP Stock Return by Calendar Year

NovaBridge Biosciences (NBP) return since Jan 2020: what $10,000 became

1 year
$10,000 $2,671
−73.29%
5 years
$10,000 $204
−97.96%
Since Jan 2020
$10,000 $1,096
−89.04%

If you had invested $10,000 in NovaBridge Biosciences (NBP) at the close on January 17, 2020, the earliest close on record here, it would have been worth $1,096 at the close on October 21, 2026: −89.04% in total, −27.90% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−65.58%
2025+368.24%
2024−55.26%
2023−54.55%
2022−91.18%
2021+0.51%
2020+277.20%

As of October 21, 2026.

NBP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$46.27M—
2024$0.00−$22.23M—
2023$632.00K−$207.73M−32,868.5%
2022−$1.55M−$371.05M23,923.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$94.27M−$46.27M—
2024$0.00—−$51.43M−$22.23M—
2023$632.00K$3.90M−$48.98M−$207.73M−32,868.5%
2022−$1.55M−$36.06M−$53.08M−$371.05M23,923.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NovaBridge Biosciences (NBP) is capitalised at $158.92M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 30 employees.

NBP last closed at $1.37 on October 21, 2026. That is −$0.05 (−3.86%) against the previous close. Over the past 52 weeks the price has ranged from $1.26 to $5.19. The latest close sits 8.73% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $46.27M. Earnings per share on a trailing basis come to −0.69.

Across the 4 fiscal years on file, revenue moves from −$1.55M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.6. Daily returns over the trailing 6 years annualize to a volatility of 90.75%. The trailing one-year total return is −73.29%. Measured over 5 years, that is −54.07% a year compounded.

Growth & Income

No dividend is on file for NBP.

2026 is still running; the total return is −65.58% year to date. Across the complete calendar years on file, 2025 returned +368.24% and 2022 returned −91.18%. Of the 6 complete calendar years on file, 3 finished higher.

Peer Comparison

NovaBridge Biosciences (NBP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NovaBridge Biosciences NBP $158.92M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. NovaBridge Biosciences has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About NovaBridge Biosciences

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Visit website →